Immunostimulatory Effects of CpG-ODN Upon Dendritic Cell-Based Immunotherapy in a Murine Melanoma Model
Authors:
- Shari Pilon-ThomasSPShari Pilon-Thomas
- Wenbin LiWLWenbin Li
- Jon J. BriggsJBJon J. Briggs
- Julie DjeuJDJulie Djeu
- James J. MuléJMJames J. Mulé
- Adam I. RikerARAdam I. Riker
- 1 July 2006
- journal article
- Published by Wolters Kluwer Health in Journal of Immunotherapy
- Vol. 29 (4) , 381-387
Abstract
In this study, we examined the protective and therapeutic efficacy of the immunoadjuvant CpG in combination with dendritic cell (DC) immunotherapy in a murine melanoma model. We found that murine bone-marrow derived DC stimulated in vitro with CpG displayed both enhanced expression of maturation markers and secretion of IL-12p70 and IL-10. In addition, these matured DC demonstrated enhanced ability to stimulate antigen specific CD4+ and CD8+ T cell responses in vitro. In a protection model, C57BL/6 mice vaccinated with either antigen-pulsed immature or CpG matured DC were unable to reject a lethal B16 melanoma challenge. In contrast, long-term protection was achieved in mice vaccinated with both CpG and antigen-pulsed DC, which correlated with an enhanced antigen specific T cell immune response. In a therapeutic model of established subcutaneous B16 melanoma, C57BL/6 mice treated intratumorally with CpG and B16 lysate-pulsed DC demonstrated a reduced tumor burden and prolonged survival. In a similar model of established subcutaneous tumor, mice treated with CpG-matured DC pulsed with a melanoma peptide, TRP-2, alone were unable to achieve tumor regression. Conversely, mice that received the combined vaccine of CpG and peptide-pulsed DC displayed a reduced tumor burden. These experiments provide evidence that combined immunization with both antigen-pulsed DC and the immunoadjuvant, CpG, can lead to tumor regression and long-term survival in a murine B16 melanoma model.Keywords
This publication has 15 references indexed in Scilit:
- CpG motifs: the active ingredient in bacterial extracts?Nature Medicine, 2003
- Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapyEuropean Journal of Immunology, 2002
- CpG Motifs in Bacterial DNA and Their Immune EffectsAnnual Review of Immunology, 2002
- NK- and CD8+ T Cell-Mediated Eradication of Established Tumors by Peritumoral Injection of CpG-Containing OligodeoxynucleotidesThe Journal of Immunology, 2001
- Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naive and bone marrow transplant recipientsBlood, 2001
- Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognitionProceedings of the National Academy of Sciences, 2001
- Repeated Administration of Cytosine-Phosphorothiolated Guanine-Containing Oligonucleotides Together with Peptide/Protein Immunization Results in Enhanced CTL Responses with Anti-Tumor ActivityThe Journal of Immunology, 2000
- Immunostimulatory CpG Oligodeoxynucleotides Enhance the Immune Response to Vaccine Strategies Involving Granulocyte-Macrophage Colony-Stimulating FactorBlood, 1998
- Comparative Analysis of Murine Dendritic Cells Derived from Spleen and Bone MarrowJournal of Immunotherapy, 1998
- Identification of Tyrosinase-related Protein 2 as a Tumor Rejection Antigen for the B16 MelanomaJournal of Experimental Medicine, 1997